
New biologic approved in Scotland for hidradenitis suppurativa
Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The advice applies for use in adult patients with… Read More















